Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) EBITDA: 2015-2023

Historic EBITDA for Cellectis (CLLS) over the last 9 years, with Sep 2023 value amounting to -$20.7 million.

  • Cellectis' EBITDA rose 24.43% to -$20.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$73.4 million, marking a year-over-year increase of 32.34%. This contributed to the annual value of -$89.7 million for FY2022, which is 13.35% up from last year.
  • Cellectis' EBITDA amounted to -$20.7 million in Q3 2023, which was up 12.49% from -$23.6 million recorded in Q2 2023.
  • In the past 5 years, Cellectis' EBITDA ranged from a high of $14.4 million in Q1 2020 and a low of -$42.4 million during Q3 2021.
  • In the last 3 years, Cellectis' EBITDA had a median value of -$24.6 million in 2021 and averaged -$25.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 162.34% in 2020, then slumped by 238.13% in 2021.
  • Cellectis' EBITDA (Quarterly) stood at -$38.5 million in 2019, then fell by 1.74% to -$39.2 million in 2020, then surged by 37.29% to -$24.6 million in 2021, then spiked by 76.95% to -$5.7 million in 2022, then climbed by 24.43% to -$20.7 million in 2023.
  • Its EBITDA stands at -$20.7 million for Q3 2023, versus -$23.6 million for Q2 2023 and -$23.4 million for Q1 2023.